BDXHA
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
New
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in BDXHA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in BDXHA
N/A
BDXHA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in BDXHA also invest in...
Want more shares? Try these...
BEAR.AX was created on 2012-07-06 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. BEAR.AX seeks to generate returns that are negatively correlated to the returns of the Australian sharemarket. The Fund expects to generate a positive return when the S&P/ASX Accumulation 200 Index falls (and a negative return when the index rises).
🙌 Performance (5Yr p.a)
-6.34%
📊 Share price
$7.74 AUD
📞 COMMUNICATIONS
BCAL Diagnostics Ltd. develops screening tests for the early detection of breast cancer. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-07-21. The Company’s core activity is the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, which is available to all women. The company is developing diagnostic technology to assist in the early detection of breast cancer by identifying, measuring and validating specific biomarkers enriched in the patient’s blood. The company is engaged in the research and development of non-invasive diagnostic technologies designed to complement existing imaging technologies, such as the mammogram. Its BCAL laboratory employs liquid chromatography mass spectrometry (LCMS) platforms to build on the Company's clinical research and leverage progress. The Company’s BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring.
📊 Share price
$0.12 AUD
🧬 BIOTECHNOLOGY